PE20091427A1 - Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico - Google Patents

Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico

Info

Publication number
PE20091427A1
PE20091427A1 PE2008001991A PE2008001991A PE20091427A1 PE 20091427 A1 PE20091427 A1 PE 20091427A1 PE 2008001991 A PE2008001991 A PE 2008001991A PE 2008001991 A PE2008001991 A PE 2008001991A PE 20091427 A1 PE20091427 A1 PE 20091427A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
halogen
imidazo
imidazol
Prior art date
Application number
PE2008001991A
Other languages
English (en)
Inventor
Rene M Lemieux
Antonio Jose Del Moral Barbosa
Joerg Martin Bentzien
Steven Richard Brunette
Zhidong Chen
Derek A Cogan
Donghong A Gao
Alexander Heim-Riether
Joshua Courtney Horan
Jennifer A Kowalski
Michael David Lawlor
Weimin Liu
Bryan Mckibben
Craig Andrew Miller
Neil Moss
Matt Aaron Tschantz
Zhaoming Xiong
Hui Yu
Yang Yu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20091427A1 publication Critical patent/PE20091427A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DE FORMULA I, DONDE R1 ES -CN, -OCF3, HALOGENO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDO CON HALOGENO O ALQUILO C1-3, R2 ES H, CICLOALQUILO C3-6, ALQUILO C1-3 OPCIONALMENTE SUSTITUIDO CON UNO O DOS GRUPOS SELECCIONADOS DE CICLOALQUILO C3-6, -OR9, ENTRE OTROS, R3 ES H O ALQUILO C1-3 O R2 Y R3 FORMAN UN ANILLO HIDROCARBONADO SATURADO DE 3 A 7 ATOMOS DE CARBONO, DONDE UN ATOMO DE CARBONO ESTA OPCIONALMENTE REEMPLAZADO POR -O-, -S-, -S(O)-, ENTRE OTROS, R4 ES ALQUILO C1-5, CICLOALQUILO C3-6, HETEROARILO, OPCIONALMENTE SUSTITUIDO CON DE --NR9R10, -OR9, ENTRE OTROS, R5 ES H, ALQUILO C1-3, -(CH2)2OH Y -(CH2)2OCH3, R6 ES H O HALOGENO, R7 ES HALOGENO O -CF3, R9 ES H, CICLOALQUILO C3-4 O ALQUILO C1-5 EL CUAL ESTA OPCIONALMENTE SUSTITUIDO CON -OH, R10 ES H O -CH3. SON COMPUESTOS PREFERIDOS: ((S)-1-BENCILCARBAMOIL-ETIL)-AMIDA DEL ACIDO (R)-5-(4-CIANO-BENCIL)-7-(3,5-DICLORO-FENIL)-5-METIL-6-OXO-6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-CARBOXILICO, (3R)-3-(4-BROMOBENCIL)-1-(3,5-DICLOROFENIL)-3-METIL-N-{(1S)-1-METIL-2-OXO-2-[(3R)-3(1H-TETRAZOL-5-IL)PIPERIDIN-1-IL]ETIL}-2-OXO-2,3-DIHIDRO-1H-IMIDAZO[1,2-a]IMIDAZOL-5-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS EXHIBEN UN EFECTO INHIBIDOR TRAS LA INTERACCION DE LAS ICAM CON LAS LEUCOINTEGRINAS, SIENDO UTILES PARA EL TRATAMIENTO DE SINDROME DE DIFICULTAD RESPIRATORIA AGUDA, TOXICIDAD POR OXIGENO, INFARTO DE MIOCARDIO, PSORIASIS, ENTRE OTROS
PE2008001991A 2007-11-29 2008-11-27 Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico PE20091427A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99096007P 2007-11-29 2007-11-29
US4795708P 2008-04-25 2008-04-25

Publications (1)

Publication Number Publication Date
PE20091427A1 true PE20091427A1 (es) 2009-10-19

Family

ID=40193954

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001991A PE20091427A1 (es) 2007-11-29 2008-11-27 Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico

Country Status (32)

Country Link
US (1) US8552205B2 (es)
EP (1) EP2225238B1 (es)
JP (1) JP5485164B2 (es)
KR (1) KR20100101095A (es)
CN (1) CN101889011B (es)
AR (1) AR069513A1 (es)
AU (1) AU2008329909B2 (es)
BR (1) BRPI0819831A2 (es)
CA (1) CA2705583A1 (es)
CL (1) CL2008003576A1 (es)
CO (1) CO6210701A2 (es)
CY (1) CY1115857T1 (es)
DK (1) DK2225238T3 (es)
EA (1) EA017688B1 (es)
EC (1) ECSP10010196A (es)
ES (1) ES2525237T3 (es)
HK (1) HK1145683A1 (es)
HR (1) HRP20141171T1 (es)
IL (1) IL205189A (es)
MA (1) MA31905B1 (es)
MX (1) MX2010004995A (es)
MY (1) MY151004A (es)
NZ (1) NZ585640A (es)
PE (1) PE20091427A1 (es)
PL (1) PL2225238T3 (es)
PT (1) PT2225238E (es)
RS (1) RS53602B1 (es)
SI (1) SI2225238T1 (es)
TN (1) TN2010000240A1 (es)
TW (2) TWI475990B (es)
UY (1) UY31493A1 (es)
WO (1) WO2009070485A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2446352T3 (es) * 2009-06-02 2014-03-07 Boehringer Ingelheim International Gmbh Derivados de amidas del ácido 6,7-dihidro-5H-imidazo[1,2-a]imidazol-3-carboxílico
WO2010141330A1 (en) * 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
US9056858B2 (en) 2009-10-21 2015-06-16 Boehringer Ingelheim International Gmbh Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
SG194621A1 (en) * 2011-04-27 2013-12-30 Shionogi & Co 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity
TW201311678A (zh) 2011-08-03 2013-03-16 Kyowa Hakko Kirin Co Ltd 二苯并氧呯衍生物
KR102049534B1 (ko) 2011-10-03 2019-11-27 오게다 에스.에이. 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
WO2016058896A1 (en) 2014-10-14 2016-04-21 Syngenta Participations Ag Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN106631827B (zh) * 2016-12-30 2018-10-23 上海毕得医药科技有限公司 一种(1-环丙基-1-甲基)乙基胺及其盐酸盐的合成方法
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
JP2023506917A (ja) 2019-12-20 2023-02-20 バイエル・アクチエンゲゼルシヤフト 置換チオフェンカルボキサミド、チオフェンカルボン酸およびその誘導体
CN111848521A (zh) * 2020-08-26 2020-10-30 韶远科技（上海)有限公司 一种2-取代-4-烷氧基咪唑化合物的制备方法
WO2024013736A1 (en) * 2022-07-12 2024-01-18 Adama Makhteshim Ltd. Process for preparing substituted benzamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2015493A1 (es) 1968-08-12 1970-04-30 Sumitomo Chemical Co
DK123717B (da) 1968-11-25 1972-07-24 Sumitomo Chemical Co 3-(3',5'-Dihalogenphenyl)-imidazolidin-2,4-dionderivater med mirobicid virkning.
JPS5136332B1 (es) 1970-12-09 1976-10-07
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
JPS63270665A (ja) 1987-04-30 1988-11-08 Wakamoto Pharmaceut Co Ltd イミダゾ−ル誘導体
JPS63270667A (ja) 1987-04-30 1988-11-08 Wakamoto Pharmaceut Co Ltd １−ベンジルイミダゾ−ル誘導体
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
US4977270A (en) 1988-12-01 1990-12-11 Ici Americas Inc. Substituted 2,4-dioxodiazolidines and -thiadiazolidines and their use as herbicides
US4911748A (en) 1988-12-22 1990-03-27 Ici Americas Inc. Herbicidal 5-substituted-3-phenyl-imidazolidine-2,4-diones
JPH04273877A (ja) 1991-02-28 1992-09-30 Sumitomo Pharmaceut Co Ltd 新規なイミダゾール誘導体
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
JPH05188631A (ja) 1992-01-10 1993-07-30 Mita Ind Co Ltd 電子写真感光体
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
US20040006011A1 (en) 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
JP2001525797A (ja) 1996-10-28 2001-12-11 ザ ユニバーシティ オブ ワシントン ウイルスｒｎａへのミスコーディングリボヌクレオシドアナログの組込みによるウイルス変異の誘導
BR9811260A (pt) 1997-03-03 2000-08-08 Boehringer Ingelheim Pharma Pequenas moléculas úteis no tratamento de doença inflamatória
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
NZ502872A (en) 1997-08-28 2002-10-25 Novartis Ag Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases
EP1063982B1 (en) 1998-03-27 2007-02-14 Genentech, Inc. Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
WO2001007048A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001007052A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001007044A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001006984A2 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
MXPA02003977A (es) 1999-10-20 2003-09-25 Tanabe Seiyaku Co Inhibidores de adhesion de celula mediada por al°2.
WO2002050080A1 (en) 2000-12-19 2002-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
RU2003126188A (ru) * 2001-01-26 2005-03-27 Бристол-Маерс Сквибб Компани (Us) Имидазолильные производные как ингибиторы кортикотропин-рилизинг фактора
US20030232817A1 (en) 2002-05-29 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful for the treatment of inflammatory disease
US6844360B2 (en) 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
US6852748B1 (en) 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
WO2006014828A1 (en) 2004-07-27 2006-02-09 Boehringer Ingelheim International, Gmbh Synthesis of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides
US7572921B2 (en) 2005-04-05 2009-08-11 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
EP1868603A1 (en) 2005-04-06 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG DERIVATIVES OF Ý6,7-DIHYDRO-5HIMIDAZO Ýl,2-ALPHA¨IMIDAZOLE-3-SULFONYL¨-AZETEDINE-CARBOXYLIC ACIDS, ESTERS AND AMIDES AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS
KR20080025067A (ko) * 2005-05-19 2008-03-19 베링거 인겔하임 인터내셔날 게엠베하 6,7-디하이드로-5Ｈ-이미다조[1,2-ａ]이미다졸-3-설폰산의유도체
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
CL2008003511A1 (es) 2007-11-29 2010-02-19 Metabasis Therapeutics Inc Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
JP2009149609A (ja) 2007-11-29 2009-07-09 Sumitomo Chemical Co Ltd アミド化合物及びその用途
EP2080758A3 (de) 2007-11-29 2009-08-26 Bayer CropScience AG Halogen substituierte delta-1-Pyrroline
WO2010141330A1 (en) 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
ES2446352T3 (es) 2009-06-02 2014-03-07 Boehringer Ingelheim International Gmbh Derivados de amidas del ácido 6,7-dihidro-5H-imidazo[1,2-a]imidazol-3-carboxílico

Also Published As

Publication number Publication date
UY31493A1 (es) 2009-07-17
EA017688B1 (ru) 2013-02-28
PL2225238T3 (pl) 2015-03-31
CY1115857T1 (el) 2017-01-25
KR20100101095A (ko) 2010-09-16
CN101889011B (zh) 2014-05-28
JP2011505359A (ja) 2011-02-24
US20110224188A1 (en) 2011-09-15
TWI475990B (zh) 2015-03-11
BRPI0819831A2 (pt) 2019-09-24
HK1145683A1 (en) 2011-04-29
AU2008329909A1 (en) 2009-06-04
MA31905B1 (fr) 2010-12-01
WO2009070485A1 (en) 2009-06-04
MX2010004995A (es) 2010-05-20
HRP20141171T1 (hr) 2015-01-30
TW201417810A (zh) 2014-05-16
EA201000866A1 (ru) 2010-12-30
MY151004A (en) 2014-03-31
AU2008329909A8 (en) 2010-06-03
RS53602B1 (en) 2015-02-27
EP2225238B1 (en) 2014-09-03
AR069513A1 (es) 2010-01-27
EP2225238A1 (en) 2010-09-08
US8552205B2 (en) 2013-10-08
ES2525237T3 (es) 2014-12-19
CA2705583A1 (en) 2009-06-04
TWI475991B (zh) 2015-03-11
AU2008329909B2 (en) 2013-10-03
IL205189A0 (en) 2010-12-30
PT2225238E (pt) 2014-12-18
TN2010000240A1 (en) 2011-11-11
IL205189A (en) 2014-09-30
NZ585640A (en) 2011-03-31
ECSP10010196A (es) 2010-07-30
CO6210701A2 (es) 2010-10-20
SI2225238T1 (sl) 2014-12-31
WO2009070485A8 (en) 2014-08-14
CN101889011A (zh) 2010-11-17
DK2225238T3 (en) 2014-11-24
TW200922562A (en) 2009-06-01
JP5485164B2 (ja) 2014-05-07
CL2008003576A1 (es) 2010-02-12

Similar Documents

Publication Publication Date Title
PE20091427A1 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
PE20140161A1 (es) Compuesto biciclico
AR050698A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto
AR059977A1 (es) Compuesto de ciclohexil piperidinil dihidrobenzimidazol composicion farmaceutica que lo comprende su uso para la preparacion de un medicamento proceso para preparalo y compuesto intermediario para la sintesis del mismo
AR038419A1 (es) Derivados de piridina y quinolina
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
CO6220952A2 (es) Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ECSP088293A (es) Inhibidores de gamma secretasa, de sulfonamido n-cíclico puenteado
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
GB0507601D0 (en) Compounds
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed